The First DMD Clinical Base Editing Drug! DMD Treatment is Entering the Gene Editing Era!
On September 06, 2024, GenAssist Ltd (GenAssist), announced that the first DMD patient has been successfully dosed with its base editing drug, GEN6050X injection, in an investigator-initiated trial (IIT). “To date, no gene editing drug has entered clinical trials for DMD indication. This first-in-human dosing marks that DMD treatment has entered the gene editing era”, […]